Biotech's 'Asset Sale' Trap: Build Generational Companies Instead
Jake Becraft critiques biotech's short-term 'asset sale' model. Learn why patient capital and a long-term vision like Amazon or SpaceX beat quick exits.
Reimagining Biotech with Jake Becraft of Strand Therapeutics — Tim’s Founder Kitchen
Jake Becraft, CEO of Strand Therapeutics, discusses the company's RNA genetic medicine technology for cancer, highlighting a patient's remarkable recovery from stage 4 melanoma via the abscopal effect. He critically analyzes the US biotech regulatory landscape, advocating for streamlined clinical trials, and contrasts it with faster international approaches. Becraft also shares lessons on effective advocacy and "platform therapeutics" as a long-term strategy, drawing parallels to companies like SpaceX and Amazon.
Key takeaways
- The traditional US biotech capital market is built for "asset sales," where over 90% of companies take an idea from concept to early evidence, then sell it off. Jake Becraft of Strand Therapeutics compares this to real estate development. Read more →
- There's a chasm between a 'good drug' (it works) and a 'good product' (it's scalable, accessible, and affordable for many). Don't confuse the two. Read more →
- Jake Becraft, CEO of Strand Therapeutics, argues that influencing policymakers and investors in deep tech like biotech isn't about data dumps; it's about emotional connection. His rule: "No one will learn until they care." Read more →
- Strand Therapeutics, led by CEO Jake Becraft, developed an RNA genetic medicine that instructs cancer cells to send immune-activating signals. Read more →
- Strand Therapeutics uses RNA to reprogram diseased cells, turning them into active participants in their own destruction rather than passive targets. Read more →
- The United States is "massively losing" to China in biotech clinical trials because China has built an "industrialized clinical trial infrastructure" that is faster and cheaper. Read more →
9 articles from this episode
Genetic Medicine: 'Delivery' is Potency, Specificity, & Transport
Jake Becraft reveals why genetic medicine's 'delivery' problem isn't one issue, but three: potency, specificity, and the transport mechanism. Apply his framework.
Good Drug vs. Good Product: Becraft's Biotech Delivery Paradox
Jake Becraft of Strand Therapeutics reveals the 'Genetic Medicine Development Paradox,' pushing founders to solve for product scalability beyond just discovery.
Good Drug vs. Good Product: Becraft's Biotech Scaling Rule
Jake Becraft reveals why a drug that works for one patient can still be a terrible product for millions. Learn his rule for scalable biotech impact.
Make Them Care First: Biotech's Policy Influence Blueprint
Jake Becraft's framework for founders: move policymakers and investors from skepticism to consensus by telling urgent stories, offering solutions, not just complaints.
Strand’s RNA Drug Teaches Cancer Cells to Self-Destruct
Jake Becraft reveals how Strand Therapeutics’ RNA genetic medicine programs cancer cells to activate the immune system, causing widespread tumors to disappear.
Reprogramming Cancer: Strand's RNA Triggers System-Wide Response
Jake Becraft reveals how Strand Therapeutics uses RNA to make cancer cells fight themselves. Learn about the 'abscopal effect' and its implications for builders.
US Biotech: China Wins First-in-Human Trials
Jake Becraft warns US biotech is losing to China on early clinical trials. Our IND system costs millions and takes 18+ months. See the faster CTN model.
US Biotech Losing to China: A $25M Regulatory Problem
Jake Becraft of Strand Therapeutics reveals why US biotech trials cost $25M and 18 months, ceding ground to China. He proposes a new CTN system to accelerate drug testing.
More The Tim Ferriss Show episodes
- Why Kids Can Learn 10x Faster Than We Think — Niels Hoven of Mentava (Tim Coaching Session)Sep 13 · 3 articles
- Dr. Andrew Huberman — Peptides, Performance, and ProtocolsJul 26 · 4 articles
- The Random Show! Mortality, AI, Supplements, Rock Climbing, & MoreJul 19 · 5 articles
- The Legendary Hollywood Power Broker — Guy Oseary on 36 Years of Managing Madonna, 26 IPOs, and MoreJul 12 · 6 articles